A randomized, controlled, double-blind study of light emitting diode photomodulation for the prevention of radiation dermatitis in patients with breast cancer.

BACKGROUND AND OBJECTIVES: Radiation dermatitis occurs in a majority of patients with breast cancer who receive radiation therapy (RT), causes significant pain, and may necessitate treatment delay. Light emitting diode (LED) photomodulation has been reported to minimize radiation dermatitis. This study sought to further evaluate the efficacy of LED photomodulation in lessening radiation dermatitis. MATERIALS & METHODS: After surgery, patients with breast cancer received LED photomodulation or sham treatments in conjunction with three-dimensional conformal RT. Reactions were evaluated using standardized photographs graded according to National Cancer Institute criteria. RESULTS: In the LED treatment group (n=18), no patients had grade 0 reactions, six (33.3%) had grade 1 reactions, 12 (66.7%) had grade 2 reactions, and none had a grade 3 reaction. In the sham treatment group (n=15), one (6.6%) patient had a grade 0 reaction, four (26.7%) had grade 1 reactions, 9 (60.0%) had grade 2 reactions, and one (6.7%) had a grade 3 reaction. Two (11.1%) patients in the LED treatment group and one (6.7%) in the control group had to interrupt treatment. Differences between groups were not statistically significant. CONCLUSION: LED photomodulation did not reduce the incidence of radiation-induced skin reactions or interruptions in therapy. .

Pediatric burns with snap-cap fireworks.

Snap-caps are marketed as a relatively safe pyrotechnic (explosive) device for children 8 years and older. Individually, the snap-caps pose very little threat because the amount of explosive compounds contained in each is limited to 1 mg. However, the accidental explosion of numerous snap-caps may cause significant burns. This study highlights a series of pediatric patients who presented with severe second- and third-degree burns as a result of accidental explosion of snap-caps. Seven patients with snap-caps-related injuries were treated at the University of California, San Diego Regional Burn Center from January 1996 to April 1999. Study foci included 1) mode and extent of injury, 2) management, 3) associated morbidity, and 4) functional outcome. Six patients (84%) required hospital admission. Four patients (57%) underwent split-thickness skin grafting to repair mean TBSA burns of 4.1% (range, 2-8%). Three patients (43%) received aggressive management of burns with topical medications and dressing changes. The nature and extent of snap-cap injuries support the contention that snap-caps have the potential to harm children to whom they are marketed.

TNF-alpha inhibitors and congestive heart failure.

Tumor necrosis factor-alpha inhibitors are among the new class of drugs that offer new options for psoriasis control. In addition to serving as a key mediator in psoriasis, elevated tumor necrosis factor-alpha levels have also been observed in patients with congestive heart failure, and clinical trials have been performed to examine the effects of tumor necrosis factor-alpha inhibitors, such as etanercept and infliximab, in such a population. Two large-scale trials examining the effects of etanercept in more than 2000 patients with heart failure did not indicate any increased risk of mortality or morbidity, and no US Food and Drug Administration warning has been issued regarding the use of etanercept in such a patient population. On the other hand, a study with infliximab showed significantly increased deaths, hospitalizations, and morbidity. Thus, infliximab>5 mg/kg is now contraindicated in patients with moderate-to-severe congestive heart failure (New York Heart Association functional class III/IV). If infliximab must be used, it should not exceed 5 mg/kg, and patients must be followed closely.

Alcohol as a risk factor for plaque-type psoriasis.

The association between alcohol and the development of plaque-type psoriasis is complex and confusing because many of the initial studies did not control for confounding factors such as tobacco use. This article presents a literature review of the epidemiologic, case-controlled, and clinical studies that examined the relationship between alcohol and plaque-type psoriasis. Early studies showed no correlation between alcohol consumption and plaque-type psoriasis. However, as researchers began to control for confounding factors, study results often illustrated a significant correlation between alcohol use and psoriasis. Some studies suggested a relative risk factor of 8.01, particularly in men. However, the studies did not document an increased risk for plaque-type psoriasis in women who drank alcohol. We recommend that clinicians discourage patients with psoriasis from consuming alcohol, especially during periods of disease exacerbation.

Involving the patient: impact of inflammatory skin disease and patient-focused care.

Atopic dermatitis (AD) and psoriasis are common chronic inflammatory diseases that are associated with significant psychosocial morbidity and a decrease in health-related quality of life (QOL). To better understand the effects of these two diseases on quality of life, as reported in the literature, a review of all English-language articles from 1970 to 2003 was performed using PubMed. Results from these studies and surveys illustrate the profound negative impact exerted by these conditions and the importance of early and appropriate treatment. These concerns can be incorporated into patient management strategies that focus on a new model for healthcare delivery, "patient-centered care," in which QOL plays an integral role. The impact of AD and psoriasis on physical, social, psychological, and financial aspects of life should not be trivialized and must be considered with the same importance as other chronic conditions. Because psoriasis and AD are chronic conditions that require patient and/or caregiver involvement for optimal management, the concept of patient-centered care with its emphasis on effective two-way communication is particularly important and useful for the clinician.

Smoking and psoriasis.

Many early studies examining the relationship between tobacco and the development of plaque-type psoriasis suggested a significant positive correlation; however, the majority of these initial studies failed to control for alcohol consumption and presented inconsistent results. The objective of this manuscript is to perform a literature review of articles assessing the relationship between smoking and psoriasis while controlling for confounders such as alcohol consumption. Alcohol-controlled studies suggest that women who are smokers have an up to 3.3-fold increased risk of developing plaque-type psoriasis. Men who are smokers do not exhibit such an increased risk, but studies have shown that smoking more than 10 cigarettes per day by men who are psoriasis patients may be associated with a more severe expression of disease in their extremities. In addition, smoking among both men and women who are psoriasis patients has been shown to reduce improvement rates. These data demonstrate the importance of discouraging smoking, particularly among psoriasis patients.

Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use.

Cyclosporine is an immunosuppressive agent that has been shown to be effective in the treatment of psoriasis. However, its serious side effects in transplant patients have hindered many dermatologists from exploiting its therapeutic capabilities. The literature contains reports of lymphomas, internal malignancies, skin cancers, and serious infections in psoriasis patients on cyclosporine therapy. However, no study has evaluated the relative risk of these side effects in relation to the general population, nor monitored the patients for years after cyclosporine was discontinued. The recently published 5-year cohort study is the most rigorous data to date on the long-term safety of cyclosporine and shows no increased risk of lymphoma or internal malignancies. The study, however, illustrates increased risk of non-melanoma skin cancers, especially squamous cell carcinoma. Review of the literature does not suggest any increased risk of opportunistic infections or tuberculosis reactivation. These data suggest that cyclosporine in dermatologic dosage (3-5 mg/kg/d) is safe and dermatologists may consider using it.

The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis.

Tazarotene (Tazorac, Allergan, Inc.) is the first topical retinoid approved for the treatment of plaque psoriasis. It has a similar onset of action compared to potent topical steroids and has the advantage of a longer remission. The common side effects associated with the drug include skin irritation (including pruritus), erythema and a burning sensation. To overcome some of these shortcomings, it has been used in combination with steroids, calcipotriene and phototherapy. Combination therapy not only results in a decrease in adverse side effects, but also enhanced efficacy. Clinical study data have shown that combination therapy is just as important as tazarotene monotherapy, if not more.

Noise improves suprathreshold discrimination in cochlear-implant listeners.

The present study aimed to examine the effect of noise on vowel-like suprathreshold discrimination in cochlear-implant listeners. The task was to detect an increment in level at the middle harmonic (400 Hz) in the background of a seven-harmonic complex from 100 to 700 Hz in 100-Hz steps. The task was performed in the absence (control) and presence of a white noise presented over a 20-35-dB range from inaudible to loud. The present result shows that discrimination of suprathreshold harmonic stimuli was significantly enhanced, particularly at the soft signal level, with suprathreshold noise. This result suggests that tuning of the noise level is required to optimize performance of different tasks in cochlear implants.